284 related articles for article (PubMed ID: 25465164)
61. Venous Thromboembolism in Primary Nephrotic Syndrome - Is the Risk High Enough to Justify Prophylactic Anticoagulation?
Rankin AJ; McQuarrie EP; Fox JG; Geddes CC; MacKinnon B;
Nephron; 2017; 135(1):39-45. PubMed ID: 27669572
[TBL] [Abstract][Full Text] [Related]
62. Natural history and response to treatment of minimal change nephrotic syndrome.
Prabhakar KS; Prakash KC; Mani MK
J Assoc Physicians India; 1993 May; 41(5):263-5. PubMed ID: 8300454
[TBL] [Abstract][Full Text] [Related]
63. [MCNS, which secondary developed into incidental IgA nephropathy--a case report].
Tsunehisa N; Takemura T; Inui T; Kamiya H
Nihon Jinzo Gakkai Shi; 1992 Oct; 34(10):1095-9. PubMed ID: 1289609
[TBL] [Abstract][Full Text] [Related]
64. Rituximab for minimal change disease in adults: long-term follow-up.
Bruchfeld A; Benedek S; Hilderman M; Medin C; Snaedal-Jonsdottir S; Korkeila M
Nephrol Dial Transplant; 2014 Apr; 29(4):851-6. PubMed ID: 24121763
[TBL] [Abstract][Full Text] [Related]
65. [Clinical presentation and prognosis in children over 10-year-old with primary nephrotic syndrome].
Tu J; Chen CY; Yang HX; Jia Y; Geng HY; Li HR
Zhonghua Er Ke Za Zhi; 2023 Aug; 61(8):708-713. PubMed ID: 37528011
[No Abstract] [Full Text] [Related]
66. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
[TBL] [Abstract][Full Text] [Related]
67. Causes of nephrotic syndrome and nephrotic-range proteinuria are different in adult Chinese patients: A single centre study over 33 years.
Ng JK; Ma TK; Lai FM; Chow KM; Kwan BC; Leung CB; Li PK; Szeto CC
Nephrology (Carlton); 2018 Jun; 23(6):565-572. PubMed ID: 28425160
[TBL] [Abstract][Full Text] [Related]
68. Is kidney biopsy necessary in children with idiopathic nephrotic syndrome?
Bekassy Z; Lindström M; Rosenblad T; Aradóttir S; Sartz L; Tullus K
Acta Paediatr; 2023 Dec; 112(12):2611-2618. PubMed ID: 37642221
[TBL] [Abstract][Full Text] [Related]
69. [Significance of trace deposition of immunoglobulin M in glomerular mesangium in children with minimal change nephrotic syndrome].
Li ZH; Xia TH; Duan CR; Wu TH; Xun M; Yin Y; Ding YF; Zhang Y; Zhang L
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Mar; 17(3):222-6. PubMed ID: 25815488
[TBL] [Abstract][Full Text] [Related]
70. A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.
Dekkers MJ; Groothoff JW; Zietse R; Betjes MG
BMC Res Notes; 2015 Jun; 8():266. PubMed ID: 26112053
[TBL] [Abstract][Full Text] [Related]
71. Prediction in idiopathic membranous nephropathy.
Marx BE; Marx M
Kidney Int; 1999 Aug; 56(2):666-73. PubMed ID: 10432407
[TBL] [Abstract][Full Text] [Related]
72. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.
Chin HJ; Chae DW; Kim YC; An WS; Ihm C; Jin DC; Kim SG; Kim YL; Kim YS; Kim YG; Koo HS; Lee JE; Lee KW; Oh J; Park JH; Jiang H; Lee H; Lee SK
J Am Soc Nephrol; 2021 Jan; 32(1):199-210. PubMed ID: 33168602
[TBL] [Abstract][Full Text] [Related]
73. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse.
Fujimoto S; Yamamoto Y; Hisanaga S; Morita S; Eto T; Tanaka K
Am J Kidney Dis; 1991 Jun; 17(6):687-92. PubMed ID: 2042651
[TBL] [Abstract][Full Text] [Related]
74. Adult-onset minimal change disease: the significance of histological chronic changes for clinical presentation and outcome.
Stefan G; Busuioc R; Stancu S; Hoinoiu M; Zugravu A; Petre N; Mircescu G
Clin Exp Nephrol; 2021 Mar; 25(3):240-250. PubMed ID: 33090339
[TBL] [Abstract][Full Text] [Related]
75. Influence of acute kidney injury on the time to complete remission in adult minimal change nephrotic syndrome: a single-centre study.
Komukai D; Hasegawa T; Kaneshima N; Takayasu M; Sato Y; Hirose M; Yoshimura A
Nephrology (Carlton); 2016 Oct; 21(10):887-92. PubMed ID: 26603689
[TBL] [Abstract][Full Text] [Related]
76. Outcomes of minimal change disease without nephrotic range proteinuria.
Son HE; Yun G; Kwon EJ; Park S; Jeong JC; Kim S; Na KY; Paik JH; Chin HJ
PLoS One; 2023; 18(8):e0289870. PubMed ID: 37590275
[TBL] [Abstract][Full Text] [Related]
77. Minimal-change nephrotic syndrome in adults treated with alternate-day steroids.
Nair RB; Date A; Kirubakaran MG; Shastry JC
Nephron; 1987; 47(3):209-10. PubMed ID: 3683690
[TBL] [Abstract][Full Text] [Related]
78. Tacrolimus Monotherapy after Intravenous Methylprednisolone in Adults with Minimal Change Nephrotic Syndrome.
Li X; Liu Z; Wang L; Wang R; Ding G; Shi W; Fu P; He Y; Cheng G; Wu S; Chen B; Du J; Ye Z; Tao Y; Huo B; Li H; Chen J
J Am Soc Nephrol; 2017 Apr; 28(4):1286-1295. PubMed ID: 27807213
[TBL] [Abstract][Full Text] [Related]
79. Glomerular Hypertrophy Is a Risk Factor for Relapse in Minimal Change Disease Patients.
Lee SW; Yu MY; Baek SH; Ahn SY; Kim S; Na KY; Chae DW; Chin HJ
Nephron; 2016; 132(1):43-50. PubMed ID: 26641085
[TBL] [Abstract][Full Text] [Related]
80. Long-term outcome of adult-onset minimal-change nephropathy.
Mak SK; Short CD; Mallick NP
Nephrol Dial Transplant; 1996 Nov; 11(11):2192-201. PubMed ID: 8941578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
